Instil Bio, Inc.
Axion Bio, Inc. (Nasdaq: AXBIO) is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities in diseases with significant unmet medical need. The company operates through its wholly owned subsidiary, Axion Bio, Inc., and maintains its corporate presence at www.axionbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Instil Bio, Inc. does
In the company’s own words
Axion Bio, Inc. (Nasdaq: AXBIO) is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities in diseases with significant unmet medical need. The company operates through its wholly owned subsidiary, Axion Bio, Inc., and maintains its corporate presence at www.axionbio.com.
The company's strategic focus centers on pursuing potential acquisitions or in-licensing of therapeutic candidates to build a pipeline of novel treatments. Historically, Axion Bio's development efforts concentrated on cell therapies, including a proprietary folate receptor alpha co-stimulatory antigen receptor tumor infiltrating lymphocyte cell therapy platform designed for cancer treatment. In August 2024, the company in-licensed AXN-2510, a bispecific antibody targeting programmed death-ligand 1 and vascular endothelial growth factors for solid tumor cancers from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. However, in January 2026, the company announced the discontinuation of AXN-2510 development and terminated its license and collaboration agreement with ImmuneOnco, leaving the company without an active product candidate in development.
As a clinical-stage biotechnology company, Axion Bio currently does not generate product revenue and operates as a development-focused entity. The company has incurred significant losses since inception and identified substantial doubt regarding its ability to continue as a going concern. Management expects ongoing losses for the foreseeable future and anticipates the need for substantial additional funding to meet financial obligations and pursue business objectives.
The company operates in a highly competitive biotechnology and pharmaceutical landscape characterized by rapid technological evolution and intense competition for intellectual property, talent, and clinical trial resources. Axion Bio faces competition from major pharmaceutical companies, specialty pharmaceutical firms, and emerging biotechnology enterprises, many possessing significantly greater financial resources and expertise in research and development, manufacturing, regulatory affairs, and commercialization.
The company's commercial success will depend substantially on its ability to identify and acquire promising therapeutic candidates, obtain and maintain robust patent protection, navigate complex regulatory approval processes with the FDA and international authorities, and ultimately develop and commercialize approved products. Axion Bio's strategy emphasizes leveraging its experience and approach to identify acquisition and in-licensing opportunities that address significant therapeutic gaps in oncology and other disease areas.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- DALLAS, TX
- Fiscal year end
- December
- CIK
- 1789769
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Instil Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Instil Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Instil Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Instil Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Instil Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”